The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A meta-analysis of comparing EGFR-TKI with chemotherapy as the second-line treatment of NSCLC patients with wild-type EGFR.
Guanghui Gao
No relevant relationships to disclose
Shengxiang Ren
No relevant relationships to disclose
Aiwu Li
No relevant relationships to disclose
Yayi He
No relevant relationships to disclose
Xiaoxia Chen
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Fei Zhou
No relevant relationships to disclose
Shuai Li
No relevant relationships to disclose
Caicun Zhou
No relevant relationships to disclose